Moderna (MRNA) Advances But Underperforms Market: Key Facts

The most recent trading session ended with Moderna (MRNA) standing at $34.71, reflecting a +0.26% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a rise of 0.85%, and the technology-dominated Nasdaq saw an increase of 0.31%.The the stock of biotechnology company has risen by 4.94% in the past month, leading the Medical sector's loss of 0.88% and the S&P 500's loss of 7.69%.Analysts and investors alike will be keeping a close eye on the performance of Moderna in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$2.90, reflecting a 5.54% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $142.28 million, showing a 14.8% drop compared to the year-ago quarter.In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$10.03 per share and a revenue of $2.2 billion, indicating changes of -13.08% and -31.9%, respectively, from the former year.Investors should also note any recent changes to analyst estimates for Moderna. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 15.05% lower. As of now, Moderna holds a Zacks Rank of #3 (Hold).The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 73, this industry ranks in the top 30% of all industries, numbering over 250.The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moderna, Inc. (MRNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks